← Back to patent-cliff list
富马酸福莫特罗/格隆溴铵
Tier C — Watch / tradeFormoterol Fumarate/Glycopyrrolate
阿斯利康
Originator
2016
First approval
-
Expiry (public)
$0.06B ▲
Peak sales
化学药
Type
Targets：mAChRs、ADRB2
Brand：Bevespi Aerosphere
Indications (approved)：慢性阻塞性肺疾病
Regional status
US
批准上市
2016-04-25
EU
批准上市
2018-12-18
China
批准上市
2020-05-12
Japan
批准上市
2019-06-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Formoterol Fumarate/Glycopyrrolate?
Approved indications include: 慢性阻塞性肺疾病.
When does the Formoterol Fumarate/Glycopyrrolate patent expire?
No public expiry year is available for Formoterol Fumarate/Glycopyrrolate yet; this page updates once verified.
How do I get a quote for Formoterol Fumarate/Glycopyrrolate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24